Biogen Idec BIIB reported a 57% rise in its fourth-quarter profit.
Biogen Idec's quarterly net profit surged to $457.3 million, or $1.92 per share, versus $292.1 million, or $1.23 per share, in the year-ago period. Excluding one-time items, it earned $2.34 per share, versus analysts' estimates of $2.28 per share.
Its total sales climbed 39% to $1.97 billion, versus analysts' estimates of $1.93 billion.
Biogen Idec shares closed at $305.65 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in